Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS
· Delayed Price · Currency is USD
0.0508
+0.0008 (1.64%)
Aug 15, 2025, 11:34 AM EDT
Oncotelic Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
26
Market Cap
22.10M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 105.45M |
| Glass House Brands | 221.55M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.09M |
| Silence Therapeutics | 27.17M |
| Longduoduo Company | 4.99M |
Oncotelic Therapeutics News
- 12 days ago - OTCQB Venture Virtual Investor Conference Agenda Announced for August 7th - GlobeNewsWire
- 4 weeks ago - SAPU Bioscience Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients - GlobeNewsWire
- 4 weeks ago - Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients - GlobeNewsWire
- 7 weeks ago - Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm - GlobeNewsWire
- 4 months ago - Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023 - GlobeNewsWire
- 4 months ago - Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI - GlobeNewsWire
- 5 months ago - Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference - GlobeNewsWire